Clinical Trial Update: Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies [Phase 1]

View source ↗

Summary

This Phase 1 trial of alisertib (MLN8237) in combination with brentuximab vedotin for relapsed/refractory CD30-positive lymphomas and CD30-positive solid tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• Alisertib (alisertib)

Snippet

Sponsor: Eric Bernicker, MD | Conditions: CD30-positive Lymphoma, CD30-positive Solid Tumor | Phase 1 | Status: WITHDRAWN